Paracetamol Among 53 Drugs to Fail Quality Test, Raises Safety Concerns.
India's drug regulator, the Central Drugs Standards Control Organisation (CDSCO), has declared 53 top-selling drugs, including paracetamol, as "Not of Standard Quality (NSQ) Alert" in its latest monthly drug alert list. These medications failed quality tests conducted by state drug officers through random sampling.
Failed Drugs Include:
- Vitamin Supplements: Vitamin C and D3 tablets Shelcal, vitamin B complex and vitamin C softgels
- Medications for Chronic Conditions: Anti-diabetic drug Glimepiride, high blood pressure drug Telmisartan
- Antibiotics: Clavam 625, Pan D, Cepodem XP 50 Dry Suspension
- Stomach Infection Treatments: Metronidazole
- Pain Relief: Paracetamol tablets IP 500 mg
Manufacturers of these drugs include Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, Pure & Cure Healthcare, and more.
Pharmaceutical companies have denied responsibility for the failed drugs, claiming they are "spurious." The CDSCO has shared two lists of failed drugs, with one containing 48 popular drugs and the second list featuring five additional drugs along with responses from pharmaceutical companies.
This development comes after the CDSCO banned 156 fixed-dose drug combinations in August, citing potential risks to humans. The banned medicines included popular fever drugs, painkillers, and allergy tablets.
Keywords :
Paracetamol, Drug Quality, Government Test, Pharmaceutical Companies, India, Medicines, Safety Concerns, Substandard Drugs, CDSCO (Central Drugs Standards Control Organisation), NSQ Alert (Not of Standard Quality), Spurious Drugs, Pharmaceutical Industry, Healthcare, Medicine Regulation, Quality Control, Public Health, Indian pharmaceutical industry quality concerns, Failed drug quality tests in India, Paracetamol quality issues, Government regulation of medicines, Substandard medicines in India.
0 Comments